Clinical implications of molecular heterogeneity in triple negative breast cancer

Breast

Volumn 24, Issue , 2015, Pages S36-S40

  Lehmann, Brian D ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Androgen receptor; Chemotherapy; Neoadjuvant; PIK3CA; TNBCtype

Indexed keywords

AFATINIB; ANTHRACYCLINE; ANTIANDROGEN; BEVACIZUMAB; BICALUTAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IXABEPILONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOTCH RECEPTOR; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROGESTERONE RECEPTOR; PROTEIN MCL 1; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY SENSITIVITY; CLINICAL HETEROGENEITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENERAL ASPECTS OF DISEASE; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; MCL1 GENE; MOLECULAR HETEROGENEITY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUTATIONAL ANALYSIS; ONCOGENE MYC; OVERALL SURVIVAL; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTIONAL HETEROGENEITY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; FEMALE; GENETICS; MUTATION; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; GENETIC HETEROGENEITY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE; TRANSCRIPTION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84948720830     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.07.009     Document Type: Article

References (55)

1. Amirikia K.C., Mills P., Bush J., Newman L.A. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 2011, 117:2747-2753.
2. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 2006, 295:2492-2502.
3. Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
4. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res 2007, 13:4429-4434.
5. Mieog J.S.D., van der Hage J.A., van de Velde C.J.H. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007, CD005002.
6. Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2011, 17:1082-1089.
7. Couch F.J., Hart S.N., Sharma P., Toland A.E., Wang X., Miron P., et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015, 33:304-311.
8. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153.
9. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28:375-379.
10. Tutt A., Ellis P., Kilburn L. TNT: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer December 2014, San Antonio, TX Abstract S3-01.
11. Timms K.M., Abkevich V., Hughes E., Neff C., Reid J., Morris B., et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014, 16:475.
12. Kaufman B., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., Balmaña J., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015, 33:244-250.
13. Pogoda K., Niwinska A., Murawska M., Olszeqski W., Nowecki Z. The outcome of special histologic types of triple-negative breast cancer (TNBC). J Clin Oncol 2014, 32:5s. (Suppl; Abstr 1122).
14. Wetterskog D., Lopez-Garcia M.A., Lambros M.B., A'Hern R., Geyer F.C., Milanezi F., et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012, 226:84-96.
15. Tognon C., Knezevich S.R., Huntsman D., Roskelley C.D., Melnyk N., Mathers J.A., et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002, 2:367-376.
16. Huober J., Gelber S., Goldhirsch A., Coates A.S., Viale G., Öhlschlegel C., et al. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012, 23:2843-2851.
17. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
18. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
19. Kriegsmann M., Endris V., Wolf T., Pfarr N., Stenzinger A., Loibl S., et al. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget 2014, 5:9952-9965.
20. Wang K., Zhang Q., Li D., Ching K., Zhang C., Zheng X., et al. PEST domain mutations in notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor. Clin Cancer Res Off J Am Assoc Cancer Res 2015, 21(6):1487-1496.
21. Balko J.M., Giltnane J.M., Wang K., Schwarz L.J., Young C.D., Cook R.S., et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014, 4:232-245.
22. Martins M.M., Zhou A.Y., Corella A., Horiuchi D., Yau C., Rakshandehroo T., et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov 2015, 5:154-167.
23. Fang C., D'Souza B., Thompson C.F., Clifton M.C., Fairman J.W., Fulroth B., et al. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1). ACS Med Chem Lett 2014, 5:1308-1312.
24. Vollebergh M.A., Klijn C., Schouten P.C., Wesseling J., Israeli D., Ylstra B., et al. Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases. PLoS One 2014, 9:e103177.
25. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
26. Sorlie T., Sorlie T., Perou C.M., Perou C.M., Tibshirani R., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
27. Lehmann B.D., Pietenpol J.A. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014, 232:142-150.
28. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
29. Burstein M.D., Tsimelzon A., Poage G.M., Covington K.R., Contreras A., Fuqua S., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2015, 21(7):1688-1698.
30. Weigelt B., Ng C.K.Y., Shen R., Popova T., Schizas M., Natrajan R., et al. Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Mod Pathol 2015, 28(3):340-351.
31. Prat A.A., Parker J.S.J., Karginova O.O., Fan C.C., Livasy C.C., Herschkowitz J.I.J., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
32. Mayer I.A., Abramson V.G., Lehmann B.D., Pietenpol J.A. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res Off J Am Assoc Cancer Res 2014, 20:782-790.
33. Adams S., Gray R.J., Demaria S., Goldstein L., Perez E.A., Shulman L.N., et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014, 32:2959-2967.
34. Denkert C., Minckwitz Von G., Brase J.C., Sinn B.V., Gade S., Kronenwett R., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015, 33(9):983-991.
35. Pembrolizumab shows potential in breast cancer. Cancer Discov 2015, 5:100-101.
36. Stirzaker C., Zotenko E., Song J.Z., Qu W., Nair S.S., Locke W.J., et al. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat Commun 2015, 6:5899.
37. Masuda H, Baggerly KA, Wang Y, Ya Z, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. J Clin Oncol:31.
38. Lehmann B.D., Bauer J.A., Schafer J.M., Pendleton C.S., Tang L., Johnson K.C., et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014, 16:406.
39. Gucalp A., Tolaney S., Isakoff S.J., Ingle J.N., Liu M.C., Carey L.A., et al. Phase II trial of bicalutamide in patients with androgen receptor positive, hormone receptor negative metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2013, 19(19):5505-5512.
40. Schneider B.P., Gray R.J., Radovich M., Shen F., Vance G., Li L., et al. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res Off J Am Assoc Cancer Res 2013, 19:1281-1289.
41. Linderholm B.K., Hellborg H., Johansson U., Elmberger G., Skoog L., Lehtiö J., et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009, 20:1639-1646.
42. Mrózek E., Layman R., Ramaswamy B., Lustberg M., Vecchione A., Knopp M.V., et al. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer 2014, 14:228-234.
43. Brodowicz T., Lang I., Kahan Z., Greil R., Beslija S., Stemmer S.M., et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. Br J Cancer 2014, 111:2051-2057.
44. Minckwitz von G., Loibl S., Untch M., Eidtmann H., Rezai M., Fasching P.A., et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto). Ann Oncol 2014, 25:2363-2372.
45. Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015, 33:13-21.
46. Bender R.J., Mac Gabhann F. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One 2013, 8:e61788.
47. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
48. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2004, 10:5367-5374.
49. Hoadley K.A., Weigman V.J., Fan C., Sawyer L.R., He X., Troester M.A., et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007, 8:258.
50. Trédan O., Campone M., Jassem J., Vyzula R., Coudert B., Pacilio C., et al. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. Clin Breast Cancer 2015, 15:8-15.
51. Schuler M., Awada A., Harter P., Canon J.L., Possinger K., Schmidt M., et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2012, 134:1149-1159.
52. Carey L.A., Rugo H.S., Marcom P.K., Mayer E.L., Esteva F.J., Ma C.X., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012, 30:2615-2623.
53. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
54. Mueller K.L., Madden J.M., Zoratti G.L., Kuperwasser C., List K., Boerner J.L. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res 2012, 14:R104.
55. D'Andrea AD1, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003 Jan, 3(1):23-34.